Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC). METHODS: In a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxali...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Chen, Zhendong, Fang, Weijia, Ren, Zhenggang, Xu, Ruocai, Ryoo, Baek-Yeol, Meng, Zhiqiang, Bai, Yuxian, Chen, Xiaoming, Liu, Xiufeng, Xiao, Juxiang, Ho, Gwo Fuang, Mao, Yimin, Wang, Xin, Ying, Jieer, Li, Jianfeng, Zhong, Wenyan, Zhou, Yu, Siegel, Abby B., Hao, Chunyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995104/
https://www.ncbi.nlm.nih.gov/pubmed/36455168
http://dx.doi.org/10.1200/JCO.22.00620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995104/
https://www.ncbi.nlm.nih.gov/pubmed/36455168
http://dx.doi.org/10.1200/JCO.22.00620

Ejemplares similares